New Orleans, Louisiana – Fibronostics has announced the acquisition of STONE Diagnostics (https://stonediagnostics.com/). According to the company announcement Fibronostics is a global health technology company that specializes in developing non-invasive diagnostic solutions for chronic diseases, with a particular focus on liver and metabolic disorders. The company’s main platform, LIVERFASt, allows clinicians to assess liver health with speed, accuracy, and scalability. A key part of its growth strategy was the acquisition of Stone Clinical Laboratories, a move that expanded its U.S. laboratory infrastructure and operational expertise. This acquisition enhances the company’s ability to innovate in diagnostics for MASH and MASLD and strengthens its collaborations with pharmaceutical and healthcare partners. Fibronostics partners with global pharmaceutical firms, diagnostic labs, and healthcare systems to advance liver diagnostics and improve patient outcomes around the world.

To learn more about Fibronostics, visit https://fibronostics.com/
Company LinkedIn Page: https://www.linkedin.com/company/fibronostics/

Company Contact:

Fibronostics
615 Baronne St New Orleans, LA 70113
888-552-1603

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.